AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAR 14 - (NewsRx.com & NewsRx.net) --
by Sonia Nichols, staff medical writer -- Authors of an Australian study report using hepatitis B virus (HBV) particles to make a vaccine containing parts of the hepatitis C virus (HCV).
The vaccine, when tested on laboratory mice, raised an immune response against HCV, according to a report of the study published in the March 2001 issue of the Journal of Virology.
To date, no research efforts have produced an effective vaccine against HCV because of its multi-faceted nature. Not only does it occur in nature in several different strains, but once it infects a human, it is liable to mutate into a different form, called a quasispecies.
The novel recombinant particles developed by researchers at Sir Albert Sakzewski Virus Research Center may represent a way to overcome some of these challenges.
Only a small portion of HBV was used to develop the recombined particles. That portion, called the envelope protein, can reshape itself into particles that look like viruses and elicit an immune response.
Hans J. Netter and colleagues inserted different lengths of virus segments from a specific part of the HCV protein, called the hypervariable region 1, into specific parts of the small, reshaped HBV virus-like particles (VLPs).